New Concepts in Anxiety: (Pierre Fabre monograph series)

After more than 20 years of virtual monopoly of the anxiolytic market, benzodiazepines had become synonymous with anxiolytics. This was true not only clinically but also in animal testing where most tests were optimized for benzodiazepines. The simultaneous realization of their dependence-producing potential and their anxiolytic properties suddenly opened up the field of anxiety research, leading to an explosion of activity in all areas from the most fundamental research to drug development. This fourth volume in the Pierre Fabre monograph series attempts to convey this explosion of interest and activity, bringing together a series of chapters covering most of the new ideas in this area of intense research activity. The symposium on which this book is based took place in Castres in South-West France in April 1990 and was sponsored by the Pierre Fabre Research Centre.

Table of Contents:
Anxiety and its therapy - today and tomorrow, D.J.Nutt; the neuropsychology of anxiety and stress, J.A.Gray et al;the neuropharmacology of 5-HT in anxiety, D.G.Grahame-Smith; the role of serotonin in anxiety - behavioural approaches, M.Briley et al; 5-HT receptor mechanisms in human anxiety, J.F.W.Deakin et al; 5-HT receptors in anxiety, J.De Vry et al; 5-hydroxytryptamine (5-HT) receptor responsivity in anxiety disorders and depression, K.P.Lesch and M.Osterheider; modulations of central serotonergic neurotransmission by chronic ipsapirone in the rat, L.E.Schechter et al; anxiogenic and other effects of mCCP, a 5-HT agonist, G.Curzon et al; platelet (3H)paroxetine and (3H)imipramine binding in zacopride treated patients with generalized anxiety disorder - preliminary results, J.C.Pecknold et al; platelet imipramine binding bmax predicts response to anxiety in alprazolam treated panic disorder patients, J.C.Pecknold et al; ondansetron - a novel anti-anxiety agent, F.S.Abuzzahab; is receptor heterogeneity relevant to the anxiolytic actions of benzodiazepine receptor ligands?, P.Skolnick; central benzodiazepine receptors - quantitative positron emission tomography study in health subjects and anxious patients, P.Abadie et al; gaba-independent mechanisms of benzodiazepine action, P.Polc; benzodiaxepine dependence, S.E.File and P.K.Hitchcott; benzodiazepine withdrawal reactions - distinction from a recurrence of the pretreatment symptons, prevention and treatment, M.B.Sheikman; withdrawal symptoms after long-term benzodiazepine dependency and comparison of the abuse potential of two benzodiazepine receptor agonists, S.Apelt et al; effects of repeated administration of diazepam to rats on locomotor activity, elevated plus-maze and various brain receptors, M.B.Assie et al; comparison of acute and chronic treatment of diazepam and ritanserin in the elevated plus-maze model of anxiety, I.K.Wright et al; neurotransmitters in the dorsal periaqueductal grey and animal model of panic anxiety, F.G.Graeff; cholecystokinin tetrapeptide - a provocation agent for research in panic disorder?, J.Bradwejn et al; the lateral septum as an anxiety-inhibiting structure - a new model for anxiolytic action, E.Yadin and E.Thomas; anticonvulsant effect of some anxiolytic drugs on two models of sound-induced seizures in mice, A.Stenger et al; anxiogenic effects of scopolamine observed in rats in the elevated plus-maze, U.Falter et al; effect of anxiolytic and hyponotic drugs effects on sleep circadian rhythms in the rat, J.Laval et al; the implication of noradrenaline in anxiety, A.L.Johnston; excitatory amino acids and anxiety, D.N.Stephens et al; are glutamatergic pathways involved in the pathophysiology of anxiety?, R.Trullas et al; anti-anxiety treatments and human memory, H.V.Curran; anxiety and cognition, R.G.Lister; cognitive factors in clinical anxiety - potential relevance to therapy, M.W.Eysenck; the effects of trait-anxiety on anagram solution times, T.Dalgleish;